EXFY vs REGN · rev $142.1M vs P/E 14, rev $4.29B
Expensify Inc (EXFY) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Expensify Inc (EXFY) is a software - application company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported EXFY revenue for 2025-12-31 was $142.1M. Net income was -$21.4M. Revenue was up 2.1% from 2024-12-31 to 2025-12-31. EXFY currently screens at market cap $124.9M.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
EXFY currently screens at market cap $124.9M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the EXFY and REGN stock pages for the full models.
Not investment advice.